Investors

Delivering innovation, improving patient lives

We believe in making things better.

Whether it’s more effective or safer drug delivery, reducing the complications that often arise from patient non-compliance, or mitigating the side effects of drugs, Nemaura Pharma is dedicated to improving patient quality of life.

To continue the commercialisation of its technologies and diversification into new drug therapies and applications, Nemaura Pharma is actively seeking licensees and collaborations for unmet clinical needs. For more information, please contact us.

Key facts

Private Limited company founded in 2005

Headquarters and research facilities in the United Kingdom, Loughborough Science Park

Has patents secured or pending in multiple countries across more than 15 patent families and over 80 individual patents

Impressive pipeline of drugs under pre-clinical and clinical development, with an ANDA under review by FDA for a Blockbuster drug, and a Spin out technology floated on the US Stock Exchange, (OTCBB: NMRD)

Over $20m received to date in licensing and development payments from global licensees, and a further $15m+ investment received from private investors

To date, has been awarded five highly competitive British Government grants, and Frost & Sullivan 2016 Enabling Technology Leadership Award in Transdermal Drug Delivery

Development Pipeline.

Discover drug delivery candidates currently under development and our pipeline of future products.

Pipeline